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Abstract
Background: Distal coronary embolization (DCE) of thrombotic material occurs frequently during percutaneous
interventions for acute myocardial infarction and can alter coronary flow grades. The significance of DCE on infarct
size and myocardial function remains unsettled. The aims of this study were to evaluate the effects of DCE sufficient
to cause no-reflow on infarct size, cardiac function and ventricular remodeling in a porcine acute myocardial
infarction model.
Methods and results: Female Yorkshire pigs underwent 60 min balloon occlusion of the left anterior descending
coronary artery followed by reperfusion and injection of either microthrombi (prepared from autologous porcine
blood) sufficient to cause no-reflow (DCE), or saline (control). Animals were sacrificed at 3 h (n = 5), 3 days (n = 20)
or 6 weeks (n = 20) post-AMI. Cardiovascular magnetic resonance (CMR), serum troponin-I, and cardiac gelatinase
(MMP) and survival kinase (Akt) activities were assessed. At 3d, DCE increased infarct size (CMR: 18.8 % vs. 14.5 %,
p = 0.04; serum troponin-I: 13.3 vs. 6.9 ng/uL, p < 0.05) and MMP-2 activity levels (0.81 vs. 0.49, p = 0.002), with
reduced activation of Akt (0.06 versus 0.26, p = 0.02). At 6 weeks, there were no differences in infarct size, ventricular
volume or ejection fraction between the two groups, although infarct transmurality (70 % vs. 57 %, p< 0.04) and
ventricular thinning (percent change in mid anteroseptal wall thickness:-25.6 % vs. 0.7 %, p = 0.03) were significantly
increased in the DCE group.
Conclusions: DCE increased early infarct size, but without affecting later infarct size, cardiac function or ventricular
volumes. The significance of the later remodelling changes (ventricular thinning and transmurality) following DCE,
possibly due to changes in MMP-2 activity and Akt activation, merits further study.
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Background
Treatment of acutely occluded coronary arteries by
percutaneous coronary intervention (PCI) is the preferred
modality for patients with acute myocardial infarction
(AMI) [1]. However, even after successful reperfusion ther-
apy, reduced myocardial flow with suboptimal perfusion of
the myocardium at the tissue level (Thrombolysis in
Myocardial Infarction (TIMI) flow grades 0-2) is common,
occurring in approximately 20 % of patients at some point
during the procedure [2, 3]. In its most extreme form,
TIMI-0 or -1 flow, known as reperfusion no-reflow (NR),
has been associated with increased infarct size, reduced
recovery of ventricular function, and increased mortality
[4]. The underlying cause of NR is due to microvascular in-
jury, characterized by damage to the myocardial microvas-
culature, and microvascular obstruction (MVO), thereby
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limiting tissue level perfusion [5]. Microvascular injury has
been attributed to both the initial ischemic injury and the
effects of reperfusion injury [6].
Distal coronary embolization (DCE) of plaque and
acute thrombotic material at the arterial occlusion site
due to guide wire crossing and/or balloon inflation and
stent deployment has been identified as another import-
ant cause of microvascular injury [7]. In North America
[8], the use of thrombus aspiration catheters as an ad-
junct to PCI for ST-elevation myocardial infarction is
recommended. This recommendation stems from mor-
tality benefits observed in the TAPAS trial [9]. However,
inconsistent effects on infarct size and mortality benefits
in subsequent clinical studies have raised questions on
the routine use of these devices in Primary PCI proce-
dures for AMI [10, 11]. Currently the role of DCE and
need for therapy remain controversial.
To date, few pre-clinical studies have addressed the
effects of DCE immediately following acute ischemia on
microvascular injury, infarct size and myocardial repair
processes at early and later time points. Moreover, previ-
ous studies have utilized polystyrene microspheres as
embolization material, which may not be reflective of
the true biological process [12]. In the current study, the
objectives were to characterize by cardiovascular mag-
netic resonance (CMR) the effects of NR on myocardial
infarction and subsequent cardiac remodelling changes
following DCE of biologically active, blood clot material
in a porcine AMI model.
Methods
Microthrombi preparation and characterization
The microthrombi used for DCE were derived from
autologous porcine blood. Three mL of blood was col-
lected in a standard serum separating tube and the
resulting clot was heated to 80–90 °C until completely
dry (~2 h). The dried clot was mechanically ground and
5 mg was weighed into Eppendorf tubes, resuspended in
sterile saline to a final concentration of 2 mg/ml and
injected following 60 min of ischemia.
Microthrombi particle size was determined using a
Multisizer™ III Coulter Counter (Beckman Coulter Inc,
California, USA) and a 400 μm aperture tube. Five mg of
microthrombi was suspended in 300 mL of isoton-II elec-
trolyte solution and particle sizes were calculated over a
20s run. This was replicated three times using DCE sam-
ples from eight different animals.
To assess for coagulation effects of microthrombi, por-
cine blood was collected 1 h post injection of heparin
(3000 units) and incubated with increasing amounts of
microthrombi for 1 h at room temperature. Measure-
ments of activated clotting time (ACT) were done using
a HEMOCHRON Jr. Signature +Whole Blood Microcoa-
gulation System (ITC, Edison, NJ).
In vivo AMI model
Animal procedures were approved by the Animal Care
Committee at Sunnybrook Health Sciences Centre. Female
Yorkshire pigs (25–35 kg, Vista Village Farms, Ontario)
were sedated using a mixture of ketamine (25 mg/kg)
and atropine (0.05 mg/kg) injected I.M and then me-
chanically ventilated with 1–3 % isoflurane. Buprenor-
phine (0.05 mg/kg) was administered I.M pre- and
post-operatively and Metacam (0.2 mL/kg) PO twice
daily for 2 days for pain management. During the baseline
procedure, the left main coronary artery was engaged using
a 6Fr JL 3.0 guiding catheter (Medtronic, Minneapolis,
MN). A Twin-Pass® dual access catheter (Vascular Solu-
tions Inc, Minneapolis, MN) was placed distal to the sec-
ond diagonal branch of the left anterior descending (LAD)
coronary artery. The animals were placed in a 3.0T MRI
scanner and imaged as described below.
Following a 4–5 days period of recovery from the
baseline procedure, animals were returned to the cathe-
terization laboratory. An angioplasty balloon catheter,
2.0–2.5 mm diameter (Sprinter Legend, Medtronic,
Minneapolis, MN), depending on vessel size, was then
used to occlude the LAD artery for 60 min, at the
same position used in the baseline study. This period
of ischemic time was deliberately chosen to cause a
moderate size, patchy myocardial infarction. Previous
studies from our group have indicated that 90 min ische-
mia causes a large (20–30 % of LV), transmural infarction
with extensive MVO, while 45 min ischemia results in a
small or negligible infarct size without MVO [13, 14].
Treatment of arrhythmias with antiarrhythmic drugs (in-
cluding lidocaine, atropine, epinephrine, and amiodarone),
and/or defibrillation during the ischemic or reperfusion
period were used as required. Following ischemia, the bal-
loon was deflated and removed, and the coronary flow
grade was assessed at angiography. An over-the-wire bal-
loon catheter was then advanced to the same location and
inflated. Administration of 2.5 ml of either microthrombi
particles suspended in saline (“DCE”) or sterile saline
(“control”) was done through the guide wire port of the
over-the-wire balloon catheter, followed by a 0.5 ml saline
flush. Coronary flow grade was assessed immediately
following injection. Microthrombi particle injection
was repeated in the DCE group until TIMI-0 or
TIMI-I flow was present. The final TIMI flow grade
was again assessed at 10 min post injection. No add-
itional microthrombi particles were injected based on the
final TIMI flow grade.
Animals were subsequently imaged and sacrificed
(overdose of pentobarbital sodium injected IV) at one of
three time points: immediate (3 h post procedure (no
CMR imaging), n = 5 including control = 3 and DCE = 2),
early (3d post procedure, n = 20, 10 per group) and late
(6 weeks post procedure, n = 20, control = 11, DCE = 9).
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The study scheme and sample sizes are indicated in
Fig. 1. Troponin-I levels were measured at baseline and
at 3d.
Coronary angiography
Coronary angiograms were performed at five time points
in the study: 1) immediately post 60 min balloon infla-
tion, 2) immediately post saline or microthrombi injec-
tion, 3) at 10 min post saline or microthrombi injection,
4) at 3d post-ischemia (early group plus eight pigs in the
6 weeks group) and 5) at 6 weeks (late group).
CMR
CMR was conducted using a 3.0T whole body MR scan-
ner (MR 750, GE Healthcare, Waukesha, WI). Cardiac
gating was achieved using a peripheral plethysmograph
and an 8 channel cardiac coil was utilized for image
acquisition for all CMR scans. CMR was conducted at
baseline, at 3d and 6 weeks post-AMI. The objectives of
the baseline CMR scan were to determine cardiac function
and the myocardial perfusion territory-at-risk at the mid-
level of the LAD where the subsequent control or DCE in-
jection would occur. The risk territory was determined by
the region of enhanced myocardium following intracoron-
ary injection of dilute gadolinium-DTPA (0.015 mmol/kg
Magnevist, Bayer Healthcare) through the Twin-Pass® dual
access catheter, as previously described [15]. Perfusion
territory images were acquired using a T1-weighted inver-
sion recovery fast gradient echo (IR-FGRE typical parame-
ters: TR/TE = 5.7/2.6, flip angle = 15°, field of view = 24 ×
21.6 cm, acquisition matrix = 192 × 160, acquisition gated
to diastole). Cardiac function was characterized using a
cine steady-state-free-precession sequence (FIESTA, GE
Healthcare) with 12 to 15 short-axis slices acquired from
apex to base under breath-hold conditions (TR/TE = 4.2/
1.7, flip angle = 45°, field of view = 24 × 21.6 cm, acqui-
sition matrix = 224 × 160, eight views per segment, 20 car-
diac phases/slice).
At the endpoint scans (3 days or 6 weeks post
AMI), cine images were acquired as described above.
Gadolinium-DTPA (0.2 mmol/kg Magnevist, Bayer
Healthcare) was injected intravenously to determine in-
farct size and MVO. Late gadolinium enhancement (LGE)
imaging (imaging ten minutes following contrast injec-
tion) was utilized to characterize infarct volume and per-
sistent MVO (IR-FGRE- typical parameters: TR/TE = 4.1/
1.9 ms, flip angle = 15°, field of view = 24 × 21.6 cm, acqui-
sition matrix = 224 × 160, 2 RR intervals, inversion time
adjusted between 250 and 300 ms to null signal from nor-
mal myocardium, acquisition gated to diastole).
CMR image analysis
CMR tissue characteristics were quantified using custom
MATLAB® scripts (The Mathworks Inc., Natick, MA).
Fig. 1 Schematic showing the number of animals utilized in each experimental group. Out of 51 animals, 45 survived to the desired endpoints.
n = 5 animals were part of study 1 (no MRI, sacrificed 3 h post ischemia); n = 20 animals were part of study 2 (sacrificed at 3 days post ischemia);
n = 20 animals were part of study 3 (sacrificed 6-weeks post ischemia). A subset of animals in study 3 (Control n= 5, DCE n = 3) were imaged at
3 days post ischemia and included with the results from study 2
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Baseline perfusion territory
Volumetric values of the myocardial perfusion territory
were quantified from the baseline contrast enhanced im-
ages. Myocardial signal intensities that were two standard
deviations above mean remote myocardial signal inten-
sities were highlighted.
Infarct size
Infarct size was determined using the late gadolinium
enhancement (LGE) CMR images and are reported in
two ways: 1) percent of the overall left ventricular (LV)
mass and 2) percent of the mid LV territory at-risk based
on the baseline intracoronary gadolinium-DTPA injec-
tions prior to the infarction. The full width at half max-
imum method [16] was utilized to delineate regions of
infarcted myocardium.
Microvascular obstruction (MVO)
Early gadolinium enhancement images (EGE), acquired
2 min after intravenous contrast injection, were utilized to
characterize the presence or absence of MVO. Persistent
MVO was quantified from LGE images acquired 10 min
post injection of contrast. Regions of hypo-enhancement
within a zone of hyper-enhancement were manually traced
and volumes were represented as percent of LV mass.
Transmurality
The maximum radial transmurality was calculated for a
given myocardial slice as described previously [14], and
averaged across all infarcted, or three mid-infarct myo-
cardial slices.
Global and regional left ventricular function
Short axis cine images were analyzed using the QMass
MR software (Medis, Netherlands). Epicardial and endo-
cardial contours were traced for the end diastolic and
end systolic phases, and volumetric data were compiled.
Analysis of regional cardiac functional parameters was
conducted using the QMass MR software. The posterior
junction between the right and left ventricle was prescribed,
which allowed for the segmentation of the myocardium
based on the American Heart Association 17 segment
model [17]. Measurements of end diastolic wall thickness
were determined for segment 8 (mid-anteroseptal), which
represented the core region of the infarct.
Tissue processing
Following sacrifice, hearts were excised and sliced into
7–8 short axis sections. Tissue samples from 3d post-
AMI hearts were taken from the core-infarct of the mid
infarct slice and flash frozen in liquid nitrogen for gelatin
zymography and western blotting experiments described
below. The remaining slices were fixed in 10 % neutral
buffered formalin, and paraffin-embedded sections were
stained with hematoxylin and eosin (H&E) and reviewed
by an experienced cardiac pathologist (JB).
Gelatin zymography
Matrix metalloproteinase (MMP)-2 and -9 activities were
measured in replicate using gelatin zymography (Controls:
n = ; DCE: n = 5). Protein lysates were prepared from
ground, frozen tissue infarct samples using a non-
denaturing lysis buffer. Protein concentration was deter-
mined using a standard bicinchoninic acid assay. Protein
samples (20 μg) were separated on a 10 % Tris-Glycine gel
with 0.1 % gelatin. Gels were incubated overnight at 37 °C
in developing buffer and then stained with Coomassie
Brilliant Blue R-250 for 1 h at room temperature and
destained using a methanol, acetic acid, water (50:10:40)
solution. Gelatinolytic bands representing pro- and active
MMP-9 and MMP-2 were quantified utilizing a densitom-
eter (BioRad GS-800, Hercules, California).
Western blotting
Frozen myocardium samples from the core infarct zone
were ground and whole cell extracts were prepared. Su-
pernatants were collected and protein concentration was
measured using the bicinchoninic acid assay. Protein
samples (15–20 μg) were separated on polyacrylamide
gels using a mini-vertical electrophoresis system (60–
90 min, 120 V) and transblotted onto PVDF membranes,
and incubated overnight at 4 °C with the required pri-
mary antibodies (Table 1). Following washes, the mem-
branes were incubated with the required horseradish
Table 1 List of primary and secondary antibodies utilized for western immunoblotting experiments
Primary antibodies (Cat #) Source Supplier Dilution Application(s)
Akt (9272) Rab PC Cell Signaling Technol. 1:1000 WB
P-Akt (9271) (Ser473) Rab PC Cell Signaling Technol. 1:1000 WB
ß-Actin Mouse MC Sigma-Aldrich 1:5000 WB
Secondary antibodies (Cat #) Source Supplier Dilution Application(s)
Goat Anti-Mouse IgG-HRP Conjugate (170-6516) Goat BioRad 1:5000 WB
Anti-Rab IgG-HRP conjugate (170-6515) Goat BioRad 1:10000 WB
MC monoclonal, PC polyclonal, WB western blotting
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peroxidase-conjugated secondary antibodies (Table 1).
Protein bands were identified by chemiluminescence
(Amersham, Piscataway, NJ), followed by densitometric
quantification on a BioRad densitometer.
Statistics
Data were presented as continuous variables and expressed
as mean ± SD. Categorical variables (TIMI flow grades,
presence of MVO) were expressed in frequencies (%) and
were compared using the Fisher’s exact test. Continuous
variables (infarct size, persistent MVO size, transmurality,
global/regional cardiac function, MMP levels, and Akt
phosphorylation ratios) were expressed as mean ± SD and
statistical significance was determined using a Student’s
t-test. A p value <0.05 was considered statistically signifi-
cant. Statistical analysis was performed by the Graphpad
Prism five Software (La Jolla, CA).
Results
Characterization of microthrombi particles
The diameter of >98 % of microthrombi particles was
between 12.5 μm (aperture tube lower limit) and 100 μm
as determined using the Multisizer™ III coulter counter
(Fig. 2a). Light microscopy imaging confirmed this range
of particle size diameter (Fig. 2b). These particles were
shown to have a dose-dependent effect on lowering
activated clotting time (ACT) in blood samples collected
separately from three animals (Fig. 2c).
Animal procedures
A total of 51 pigs underwent the AMI protocol, with
88 % survival. Four pigs died during the procedure due
to ventricular arrhythmias and two pigs had sudden
death at 1d post-AMI.
3 days post-AMI
Coronary angiography
All DCE pigs had NR immediately post DCE as man-
dated by protocol (Fig. 3). In contrast, only 19 % of con-
trol pigs had NR (p = 0.0001). At 10 min following DCE
or saline injection, significant differences in TIMI flow
grade between groups were still present (p = 0.006),
although an improvement to either TIMI-2 or -3 was
observed in 1/3 of the DCE animals, while the TIMI
flow in control animals remained unchanged except in 1
case. At 3d post-AMI, TIMI flow grade in the DCE
group had improved and there were no significant differ-
ences in TIMI flow grade between groups.
Serum troponin-I biomarkers of cardiac injury
There were no baseline differences in the level of troponin-
I between the two groups. At 3d post-AMI, the DCE group
demonstrated increased serum troponin-I levels compared
to controls (13.3 ± 9.4 versus 6.9 ± 2.7 ng/uL, p < 0.05).
There were no differences between the percentage of con-
trol and DCE animals that required defibrillation during
the infarct procedure (Control: 7 of 15 animals [47 %];
DCE: 6 of 13 animals [46 %], p = 1.00).
CMR
Perfusion territory and infarct size The myocardial
perfusion territory during the baseline scan was similar
between the two groups, representing 39 % of the total left
ventricle in each group (Fig. 4a). There were no significant
differences in the baseline perfusion territory size of con-
trol animals that had TIMI 2/3 flow versus control ani-
mals that had TIMI 0/1 flow at either 10 min or 3d post
ischemia. Similar analysis with DCE animals also showed
no significant differences in perfusion territory size when
grouped based on TIMI flow at the two time points.
At 3D, LGE imaging showed a significant increase in
infarct size in the DCE group compared to controls
(18.8 ± 5.8 % versus 14.5 ± 4.4 %, p = 0.04) (Fig. 4b). Al-
though infarct size as a percent of the perfusion territory
was also higher in the DCE group, this did not reach
statistical significance (59.2 ± 15.6 % versus 44.0 ± 16.4 %,
p = 0.08) (Fig. 4b).
Microvascular obstruction (MVO) Early gadolinium
enhancement (EGE) imaging showed MVO in 12 of 13
Fig. 2 Analysis of microthrombi particles. a. Coulter counter assessment of particle size versus total number of a representative sample. >98 % of
microthrombi particles within the sample were <100 μm in diameter. b. Representative light micrographic image showing several microthrombi
particles (200× magnification). c. A representative experiment indicating a dose-related effect of microthrombi on reducing activated clotting
time (ACT)
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pigs (92 %) in the DCE group compared to 11 of 15
pigs (73 %) in the control group (p = NS, Fig. 4c). In
animals where persistent MVO was present (deter-
mined from LGE images; n = 10 per group), the average
value as a percent of LV mass was 6.4 ± 5.0 and 4.2 ± 2.4 %
in the DCE and control groups, respectively (p =NS,
Fig. 4c).
Infarct transmurality At this early time point (3d), the
mean transmurality across all infarcted slices was higher
Fig. 3 TIMI flow grades in the LAD following AMI. NR (TIMI-0 and -1 flow grades) was significantly increased immediately and at 10 min post
injection of microthrombi in the DCE group. *p = 0.0001; **p = 0.006
Fig. 4 Baseline and 3d post-infarct CMR with gadolinium-DTPA. a. Baseline myocardial perfusion territory images (seen as white enhancement) of
the mid LAD from apex to base. This territory represented 39 % of the overall left ventricular mass. b. LGE images showing regions of persistent
MVO (red arrow) and infarct tissue (yellow arrow). Infarct size as a percent of total left ventricular mass (center) was significantly increased in DCE
animals compared to controls (*p = 0.04) (Control n = 15; DCE n = 13). The DCE group also demonstrated an increased infarct size relative to the
baseline perfusion territory at-risk (p = 0.08). c. EGE images depicting MVO (Left, red arrow). A non-significant increase in the proportion of animals
displaying MVO (center) and persistent MVO (right) was observed in the DCE group
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in the DCE group as compared to controls (70 ± 9 %
versus 60 ± 17 %, p = 0.06). The average transmurality
of three mid-infarct myocardial slices displayed a simi-
lar trend, with increased transmurality in the DCE
group compared to controls (74 ± 15 % versus 60 ± 21 %,
p = 0.07).
Cardiac function No significant differences were ob-
served in global cardiac function parameters between
groups at baseline and at 3d post-AMI (Table 2). There
were also no significant differences in systolic or dia-




At 6 weeks post-AMI, all animals in both groups had
TIMI ≥ 2 flow.
CMR imaging
Infarct size and transmurality At 6 weeks, infarct size
in both groups had significant decreased by 50 %. There
were no significant differences in infarct size (measured
in grams or percent of LV mass) between the DCE group
and controls (Percent of LV mass: 7.7 ± 2.4 % versus
6.0 ± 2.1 %, respectively, p =NS) or infarct. The average
transmurality across all infarcted myocardial slices was
significantly elevated in the DCE group compared with
controls (70 ± 10 % versus 57 ± 15 %, p < 0.04, Fig. 5).
Cardiac function There was more extensive ventricular
thinning of the mid-anteroseptal segment in the
DCE group compared to controls, based on the per-
cent change in wall thickness at 6 weeks compared
to the baseline value (-25.6 % ± 21.1 % vs. 0.7 % ± 26.8 %,
p = 0.03, Fig. 5). Although there were significant increases
in ventricular systolic and diastolic volumes from baseline
to 6 weeks in both groups, no significant differences
in systolic or diastolic ventricular volumes or ejection
fraction were present between the two groups at 6 weeks
(Table 2).
Histology and molecular analyses
Histology
Tissue was studied at three time points following AMI:
3 h, 3 days and 6 weeks. There were no prominent dif-
ferences between the DCE group and controls at any of
the time points other than the anticipated presence of
thrombi with embolized material inside intramyocardial
vessels within the infarct region, at both the 3 h and
3 days time points (Fig. 6a-b). At 3 h, early markers of
myocardial damage were evident in both groups, includ-
ing myocyte edema, contraction band necrosis, and
hypereosinophilic cells (Fig. 6c). At 3d, there was exten-
sive infiltration of inflammatory cells, mainly neutrophils
and macrophages, within the infarct zone (Fig. 6d).
Epicardial and myocardial arteries and microvasculature
appeared normal in the vast majority of infarcts. At
6 weeks, aneurysm formation and myocardial wall thin-
ning was observed in both groups. Extensive myocardial
fibrosis was present, with some degree of residual in-
flammatory cell clustering at the junction of the infarct
and normal myocardium (Fig. 6e).
Matrix metalloproteinase (MMP)
At 3d post-AMI, both pro- and active MMP-2 levels
were elevated in the DCE group compared to controls
(Pro MMP-2: 1.15 ± 0.16 versus 0.80 ± 0.06, p = 0.004
and Active MMP-2: 0.81 ± 0.08 versus 0.49 ± 0.12, p =
0.002, Fig. 7). There were no significant differences in
MMP-9 levels.
Activation of survival kinase (Akt)
The ratio of phosphorylated Akt to total Akt within the
infarct zone at 3d post-AMI was significantly lower in
DCE group than in controls (0.06 ± 0.07 versus 0.26 ±
0.12, p = 0.02, Fig. 8).
Discussion
Our study demonstrates that in a well-controlled model
of moderate to severe AMI, there is an incremental ef-
fect of DCE associated with increased inflammatory
markers and larger infarct size at early time points and
increased ventricular wall thinning at later time points.
Molecular studies indicated increased MMP-2 activity
and decreased Akt phosphorylation within the infarct
Table 2 Cardiac function parameters assessed at baseline, 3 days, and 6 weeks post-AMI
Baseline 3 days 6 weeks
Control (n = 15) DCE (n = 13) Control (n = 15) DCE (n = 13) Control (n = 11) DCE (n = 9)
EDV (mL) 71.50 ± 12.70 76.31 ± 9.33 76.25 ± 12.30 79.79 ± 9.16 87.96 ± 12.67 93.43 ± 11.33
ESV (mL) 45.63 ± 11.36 50.34 ± 9.35 52.81 ± 13.02 53.27 ± 8.49 61.29 ± 12.23 63.53 ± 8.86
SV (mL) 25.87 ± 5.01 25.95 ± 3.34 23.45 ± 5.70 26.45 ± 3.75 26.67 ± 3.30 29.83 ± 6.89
EF (%) 36.71 ± 6.97 34.51 ± 6.10 31.27 ± 7.75 33.47 ± 5.05 30.72 ± 4.46 31.84 ± 5.66
EDV end diastolic volume, EF ejection fraction, ESV end systolic volume, SV stroke volume
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zone of DCE treated pigs at the early post infarct period,
suggesting potential mechanisms for the adverse changes
in late ventricular remodelling.
These studies were performed in a porcine model of
60 min of ischemic time prior to the embolization inter-
vention. This ischemic time period was carefully selected
to ensure the presence of a clinically relevant, patchy (ie
nontransmural) infarct, which would be at least moder-
ate in size. Previous work from our group has shown
that extending the ischemic time in this model to
90 min causes transmural, large infarcts with extensive
MVO that would be difficult to detect incremental dam-
age by distal embolization. Reducing the ischemic time
to 45 min produces a small or even negligible infarct
without MVO that would be less representative of the
infarct sizes typically encountered in clinical practice
[13]. Although 60 min may seem a very short ischemic
period for patients presenting with acute myocardial
infarction, Hedstrom et al have previously shown large
differences in the ischemic time required for 50 % infarc-
tion of area at risk between pigs and humans (37 min ver-
sus 288 min, respectively) [18]. The 14 % infarct size in
our control group seems consistent with the 12.7 % infarct
size documented in human studies in which the ischemic
time ranges from 2.5 to 6 h, which represents the typical
presentation time of most acute myocardial infarctions
treated by reperfusion [19]. In contrast, the infarct size of
patients presenting beyond the 6 h period was 17.9 %.
NR has been attributed to microvascular injury, due to
several factors, including endothelial cell damage, myo-
cyte swelling, inflammatory cell accumulation, reactive
oxygen species and platelet-fibrin thrombi [5]. Previous
experimental studies in animal models have suggested
that treatment of NR may not actually affect infarct size
since the microvascular damage was confined histologi-
cally to the irreversibly injured core of myocardial necro-
sis [5, 20]. However, these studies were not performed in
an AMI model with distal embolization, which com-
monly occurs during PCI reperfusion therapy. In the
current porcine AMI model, 80 % of pigs had normal
(TIMI-3) flow grade after 60 min of ischemia alone (ie.
without DCE), which still resulted in a moderate-severe
sized infarct with MVO in the majority of pigs. The NR
initially present in all of the DCE pigs immediately post
injection did improve spontaneously over the 10-min
period in 30 % of the pigs. By 3d, there were no longer
differences in NR between the DCE and control groups
(approximately 30 % in both groups). The presence of
no-reflow in control animals at 10 min/3 days and the
resolution of no-reflow in DCE animals at 10 min/3 days
could not be attributed to differences in perfusion terri-
tory size within each group and time point. The spon-
taneous improvement in TIMI flow grades following
DCE in our porcine study parallels the human setting,
where NR following primary angioplasty is frequently
transient and improves either spontaneously or in re-
sponse to vasoactive agents during the revascularization
procedure [4]. TIMI myocardial perfusion grade in pa-
tients with myocardial infarction treated with primary
angioplasty has also been shown to improve over the ini-
tial few days [21]. However, even transient NR during
PCI appears to adversely affect prognosis in patients,
Fig. 5 Infarct characterization 6 weeks post-AMI. a Top panel: Representative LGE images showing differences in infarct transmurality (infarct
indicated by arrows). Lower panel: Average infarct transmurality was increased in DCE group compared to controls (*p = 0.04) (Control n = 11;
DCE n = 9). b Top panel: Representative short axis images showing the mid-anteroseptal segment (arrows). Bottom panel: Percent change in mid
anteroseptal wall thickness at 6 weeks compared to baseline in control and DCE animals. Negative values represent wall thinning. DCE treated
pigs had increased wall thinning compared to controls (**p = 0.03) (Control n = 11; DCE n = 9)
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including in-hospital, 30 days and 6 months mortality
[22, 23].
The DCE group had a modest but non-significant
increase in persistent MVO at the early time point. In
previous studies, the presence and size of MVO predicts
larger infarct size, worse scar thinning and infarction ex-
pansion [24]. In the current study, there was an approxi-
mately 30 % increase in infarct size at 3d in the DCE
group, indicating an initially more extensive infarct in
the presence of DCE causing NR. Using CMR to deter-
mine the myocardial perfusion territory at risk, our
study demonstrated that the increased infarct size at the
early time point (3d) in DCE treated animals was due to
a more extensive infarction within the perfusion territory
at risk (59 % compared to 40 % in controls).
However, it was very interesting to note that at
6 weeks, there were no longer differences in overall in-
farct size between the two groups. There was a marked
reduction (approximately 50 %) in overall infarct size in
both groups. An AMI patient study from our group pre-
viously reported a 41 % reduction in infarct size in serial
CMRs done initially at 1–48 h post AMI and again at
2–3 weeks [25]. This infarct shrinkage has been shown to
be due to scar formation and infarct contraction [14]. Of
note, these differences in infarct size in the current por-
cine study did not alter the overall ejection fractions or
Fig. 6 a-e. Histology of mid-infarct myocardial samples (H&E staining). a Microthrombi material (black arrows) present within the myocardial
microvasculature at 3 h post-AMI (original magnification 200×). b Region of AMI showing an artery occluded by thrombus (arrow), at 3d post-AMI
(original magnification 400×). c. Infarct junction depicting contraction band change (black arrow) and normal myocardium (yellow arrow) (original
magnification 200×). d Extensive recruitment of inflammatory cells within the infarct zone at 3d post-AMI (arrow) (original magnification 25×).
e Infarct zone 6 weeks post ischemia shows a subendocardial band of preserved myocytes (black arrow), and a large zone of fibrous tissue
(yellow arrow) which has replaced the myocardium, and some residual inflammatory cells (white arrow) (original magnification 25×)
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ventricular volumes. The accentuated infarct thinning in
the DCE group would partially explain the lack of differ-
ences in infarct size between the two groups at the late
time point.
The extent of infarct transmurality has been related to
LV remodeling and dysfunction during healing following
anterior infarction [26]. Furthermore, increased infarct
transmurality measured by LGE CMR has also been
identified as a risk factor for life threatening arrhythmias
and cardiac death in patients with chronic myocardial
infarction [27].
We have previously shown that additional effects of
distal embolization include activation of inflammatory
(TNF-alpha, IL-6) and thrombotic markers as a conse-
quence of injecting inert polystyrene microspheres into
porcine coronary arteries [28]. This activation occurred
before the onset of NR, with progressive increase up to
the point of NR. In the current study, two potential
mechanisms may contribute to the remodeling changes
as a result of DCE following ischemia-reperfusion injury.
First, there was an increase in pro- and active MMP-2
levels within DCE samples compared to controls. Several
studies have indicated that increased MMP levels occur
post AMI and may adversely affect LV remodeling. In
preclinical AMI models, MMP expression and activity
increased following reperfusion [29]. It has also been
shown that MMP-2 knockout mice have lower incidence
of cardiac rupture and adverse LV remodeling [30]. Clin-
ical studies have demonstrated an association between
higher serum MMP-2 and adverse LV remodeling [31].
In our study, the increased myocardial tissue MMP-2
levels at 3d post-AMI in the DCE group may have
contributed to the proteolytic milieu that resulted in
enhanced LV infarct wall thinning at 6 weeks.
Secondly, our study showed reduced Akt phosphoryl-
ation in myocardial samples from the infarct core in the
Fig. 7 Gelatin zymography of myocardial samples at 3d post-AMI. a. Representative zymogram and densitometry values of pro- and active forms
of MMP-9 (b) and MMP-2 (c). Pro- (left) and active (right) MMP-2 levels were significantly elevated in the DCE group compared to controls. *p = 0.004,
**p = 0.002 (Control n = 4; DCE n = 5)
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DCE group compared to controls. Akt is constitutively
expressed within the myocardium and controls a myriad
of cellular functions including cell death, differentiation
and metabolism [32]. The activation (phosphorylation)
of Akt has been shown to be associated with myocyte
survival and reduction in infarct size in a number of
pre-clinical studies [33–35]. The higher level of phos-
phorylated Akt in the infarct of the control group sug-
gests that a better pro-survival tissue environment may
have contributed to the observed smaller early infarct
size and less late ventricular thinning seen in controls.
Many studies have described the effects of DCE, with-
out prior AMI, on the myocardium [28, 36–38]. These
studies relied on microspheres to simulate thrombotic
material and demonstrated altered coronary flow, con-
tractile dysfunction, and an inflammatory response [38].
Very few studies, however, have investigated the role of
microembolization following AMI. Skyschally et al. re-
cently demonstrated that injection of microspheres fol-
lowing 90 min of ischemia resulted in a significant
increase in infarct size measured using triphenyl tetrazo-
lium chloride staining [12]. Our results also illustrate an
early (3d) increase in infarct size measured using CMR.
Skyschally et al., however, did not report the late effects
of embolization. The results from our study suggest that
the differences in infarct size between groups do not
persist into the chronic phase following AMI. Moreover,
the use of microspheres by the previous studies may not
accurately reflect the endogenous embolization material.
We have utilized biologically active microthrombi derived
from porcine blood which is more representative of the
embolization material present clinically. Previous studies
have also utilized microthrombi derived from blood [39],
however, these studies have not demonstrated its effects in
the context of AMI.
Clinical relevance
Initial enthusiasm for thrombus aspiration prior to PCI
in patients with AMI was based on improvement in
angiographic assessment of perfusion [40] and a reduc-
tion in 1y mortality [9]. These studies formed the basis
of the 2013 ACCF/AHA guidelines that provided a
Class IIa indication for aspiration thrombectomy dur-
ing primary PCI for AMI [8]. However, the absence
of any effect of thrombus aspiration on infarct size or
LV function in recent CMR studies [10] or on mortality in
the randomized TASTE [11, 41] and TOTAL trial [42],
have cast doubt on the utility of this intervention. Clinical
distal embolization intervention studies are challenging
due to patient heterogeneity related to anatomic differ-
ences (the culprit coronary artery; the level of obstruction,
the thrombus burden, the period of ischemia and collat-
eral flow) and patient characteristics and co-morbidities
(age, diabetes, hypercholesterolemia, hypertensions etc.)
In the controlled experimental conditions possible in
our preclinical study, we did not observe significant
persistent differences in infarct size at 6 weeks post
infarction, and no differences in LV volumes or ejection
fraction. The effects of DCE at later time periods, such as
6 months to 1 year post infarction when remodeling
Fig. 8 Western blotting of myocardial samples at 3d post-AMI. a. Representative western blots of phosphorylated Akt from infarcted myocardium
of control and DCE treated animals at 3d post-AMI. Densitometry measurements of (b) phosphorylated Akt/total Akt ratio and (c) values normalized to
β-actin indicated increased phosphorylated Akt in controls compared to DCE. *p = 0.02, **p = 0.03 (Control n = 4; DCE n = 5)
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changes should be complete, remain to be determined in
this animal model.
Limitations
Although we have been careful to use biologically active,
thrombotic material for distal embolization, we appreciate
that this model does not include atherosclerotic plaque
material that may also be a component of the thrombus in
AMI in patients. The presence of complex plaque material
or more organized thrombotic material could alter the ex-
tent and duration of microvascular injury, since this ma-
terial may be more resistant to dissolution. Secondly,
since we only investigated a single ischemic time param-
eter, our observations are specific to the case of moderate
to severe AMI, given the overall infarct size and extent of
MVO, even in the control group. One would need to con-
sider different ischemic durations to probe further how
the impact of DCE varies with initial infarct severity. We
suspect that as the severity of the original MI increases
(longer ischemic times), there would be reduced tissue left
to damage by the DCE response. However, the current
study does seem to be relevant for the majority of AMI
patients with a high likelihood of clinical benefit by reper-
fusion therapy. Lastly, our porcine infarction model is
limited by the absence of the complexities of human co-
morbidities such as hypertension, diabetes, endothelial
dysfunction and hypercholesterolemia.
Conclusion
DCE sufficient to cause angiographic NR significantly in-
creases early infarct size without affecting global cardiac
function. However, there were no significant effects on
late infarct size or global or regional cardiac function.
The increases in infarct transmurality and wall thinning
in the DCE group at the late time point are of uncertain
clinical significance that merits further study.
Abbreviations
ACT: Activated clotting time; AMI: Acute myocardial infarction;
CMR: Cardiovascular magnetic resonance; DCE: Distal coronary embolization;
EGE: Early gadolinium enhancement; H&E: Hematoxylin and eosin; LAD: Left
anterior descending; LGE: Late gadolinium enhancement; MMP: Matrix
metalloproteinase; MVO: Microvascular obstruction; NR: No-reflow;
PCI: Percutaneous coronary intervention; TIMI: Thrombus Aspiration in
Myocardial Infarction.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
The specific roles of the authors in the study are as follow: RMT was
involved in the experimental design, analysis and interpretation of data,
and preparation of the manuscript. SYL was involved in the analysis and
interpretation of data and preparation of the manuscript. BQ was involved
in the experimental procedures, analysis and interpretation of data and
preparation of the manuscript. ABO was involved in design of the
experiments and interpretation of the data, in addition to preparation of the
manuscript. NRG was involved in the CMR analysis and interpretation of CMR
data and preparation of the manuscript. XQ was involved in the analysis and
interpretation of CMR data and preparation of the manuscript. RW was
involved in the analysis and interpretation of data and preparation of the
manuscript. ML was involved in the analysis and interpretation of data and
preparation of the manuscript. TAB was involved in the analysis and
interpretation of data and preparation of the manuscript. JB was involved in
the pathological analysis and preparation of the manuscript. MH was
involved in the experimental design and interpretation of MMP and Akt data
and preparation of the manuscript. GAW was involved in the project
conception and grant application, experimental design and interpretation of
data and preparation of the manuscript. BHS was involved in the conception
and design of the experiments and grant application, interpretation of data,
in addition to drafting and preparation of the manuscript. All authors read
and approved the final manuscript.
Author details
1Schulich Heart Centre, Sunnybrook Health Sciences Center, 2075 Bayview
Avenue, Room D-406, Toronto, ON M4N 3M5, Canada. 2Physical Sciences
Platform, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre,
Toronto, Canada. 3Toronto General Research Institute, Toronto, Canada.
4Department of Pathology, University Health Network, Toronto, Canada.
5University of Toronto, Toronto, Canada. 6Korea University Ansan Hospital,
Ansan, Korea. 7Barzilai Medical Centre, Ashkelon, Israel.
Received: 2 June 2015 Accepted: 26 October 2015
References
1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous
thrombolytic therapy for acute myocardial infarction: a quantitative review
of 23 randomised trials. Lancet. 2003;361:13–20.
2. Morishima I, Sone T, Okumura K, Tsuboi H, Kondo J, Mukawa H, et al.
Angiographic no-reflow phenomenon as a predictor of adverse long-term
outcome in patients treated with percutaneous transluminal coronary
angioplasty for first acute myocardial infarction. J Am Coll Cardiol.
2000;36:1202–9.
3. Jaffe R, Charron T, Puley G, Dick A, Strauss BH. Microvascular obstruction
and the no-reflow phenomenon after percutaneous coronary intervention.
Circulation. 2008;117:3152–6.
4. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans.
J Am Coll Cardiol. 2009;54:281–92.
5. Schwartz BG, Kloner RA. Coronary no reflow. J Mol Cell Cardiol.
2012;52:873–82.
6. Prasad A, Stone GW, Holmes DR, Gersh B. Reperfusion injury, microvascular
dysfunction, and cardioprotection: the “dark side” of reperfusion.
Circulation. 2009;120:2105–12.
7. Okamura A, Ito H, Iwakura K, Kurotobi T, Koyama Y, Date M, et al.
Clinical implications of distal embolization during coronary interventional
procedures in patients with acute myocardial infarction: quantitative study
with Doppler guidewire. JACC Cardiovasc Interv. 2008;1:268–76.
8. O’Gara PT, Kushner FG, Ascheim DD, Casey Jr DE, Chung MK, de Lemos JA,
et al. 2013 ACCF/AHA guideline for the management of ST-elevation
myocardial infarction: a report of the American College of Cardiology
Foundation/American Heart Association Task Force on Practice Guidelines.
Circulation. 2013;127:e362–425.
9. Vlaar PJ, Svilaas T, van der Horst IC, Diercks GFH, Fokkema ML, de Smet
BJGL, et al. Cardiac death and reinfarction after 1 year in the Thrombus
Aspiration during Percutaneous coronary intervention in Acute
myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet.
2008;371:1915–20.
10. Stone GW, Maehara A, Witzenbichler B, Godlewski J, Parise H, Dambrink JH,
et al. Intracoronary abciximab and aspiration thrombectomy in patients
with large anterior myocardial infarction: the INFUSE-AMI randomized trial.
JAMA. 2012;307:1817–26. doi:10.1001/jama.2012.421.
11. Frobert O, Lagerqvist B, Olivecrona GK, Omerovic E, Gudnason T, Maeng M,
et al. Thrombus aspiration during ST-segment elevation myocardial
infarction. N Engl J Med. 2013;369:1587–97.
12. Skyschally A, Walter B, Heusch G. Coronary microembolization during early
reperfusion: infarct extension, but protection by ischaemic postconditioning.
Euro Heart J. 2013;34:3314–21.
13. Ghugre NR, Ramanan V, Pop M, Yang Y, Barry J, Qiang B, et al. Quantitative
tracking of edema, hemorrhage, and microvascular obstruction in subacute
Thomas et al. Journal of Cardiovascular Magnetic Resonance  (2015) 17:106 Page 12 of 13
myocardial infarction in a porcine model by MRI. Magn Reson Med.
2011;66:1129–41.
14. Ghugre NR, Pop M, Barry J, Connelly KA, Wright GA. Quantitative magnetic
resonance imaging can distinguish remodeling mechanisms after acute
myocardial infarction based on the severity of ischemic insult. Magn Reson
Med. 2012;70:1095–105.
15. Carlsson M, Saeed M. Intracoronary injection of contrast media
maps the territory of the coronary artery: an MRI technique for assessing
the effects of locally delivered angiogenic therapies. Acad Radiol.
2008;15:1354–9.
16. Amado LC, Gerber BL, Gupta SN, Rettmann DW, Szarf G, Schock R, et al.
Accurate and objective infarct sizing by contrast-enhanced magnetic
resonance imaging in a canine myocardial infarction model. J Am Coll
Cardiol. 2004;44:2383–9.
17. Cerqueira MD. Standardized Myocardial Segmentation and Nomenclature
for Tomographic Imaging of the Heart: A Statement for Healthcare
Professionals From the Cardiac Imaging Committee of the Council on
Clinical Cardiology of the American Heart Association. Circulation.
2002;105:539–42.
18. Hedstrom E, Engblom H, Frogner F, Astrom-Olsson K, Ohlin H, Jovinge S,
et al. Infarct evolution in man studied in patients with first-time coronary
occlusion in comparison to different species - implications for assessment
of myocardial salvage. J Cardiovasc Magn Res. 2009;11:38.
19. Francone M, Bucciarelli-Ducci C, Carbone I, Canali E, Scardala R, Calabrese
FA, et al. Impact of primary coronary angioplasty delay on myocardial
salvage, infarct size, and microvascular damage in patients with ST-segment
elevation myocardial infarction: insight from cardiovascular magnetic
resonance. J Am Coll Cardiol. 2009;54:2145–53.
20. Rezkalla SH. No-Reflow Phenomenon. Circulation. 2002;105:656–62.
21. Aasa M, Kirtane AJ, Dellborg M, Gibson MC, Prahl-Abrahamsson U, Svensson
L, et al. Temporal changes in TIMI myocardial perfusion grade in relation to
epicardial flow, ST-resolution and left ventricular function after primary
percutaneous coronary intervention. Coron Artery Dis. 2007;18:513–8.
22. Mehta RH, Harjai KJ, Boura J, Cox D, Stone GW, O’Neill W, et al. Prognostic
significance of transient no-reflow during primary percutaneous coronary
intervention for ST-elevation acute myocardial infarction. Am J Cardiol.
2003;92:1445–7.
23. Chan W, Stub D, Clark DJ, Ajani AE, Andrianopoulos N, Brennan AL, et al.
Usefulness of transient and persistent no reflow to predict adverse clinical
outcomes following percutaneous coronary intervention. Am J Cardiol.
2012;109:478–85.
24. Wu KC. CMR of microvascular obstruction and hemorrhage in myocardial
infarction. J Cardiovasc Magn Res. 2012;14:68.
25. Zia MI, Ghugre NR, Connelly KA, Strauss BH, Sparkes JD, Dick AJ, et al.
Characterizing myocardial edema and hemorrhage using quantitative T2
and T2* mapping at multiple time intervals post ST-segment elevation
myocardial infarction. Circulat Cardiovasc Img. 2012;5:566–72.
26. Masci PG, Ganame J, Francone M, Desmet W, Lorenzoni V, Iacucci I, et al.
Relationship between location and size of myocardial infarction and their
reciprocal influences on post-infarction left ventricular remodelling.
Euro Heart J. 2011;32(13):1640–8.
27. Boye P, Abdel-Aty H, Zacharzowsky U, Bohl S, Schwenke C, van der Geest
RJ, et al. Prediction of life-threatening arrhythmic events in patients with
chronic myocardial infarction by contrast-enhanced CMR. JACC Cardiovasc
Img. 2011;4:871–9.
28. Charron T, Jaffe R, Segev A, Bang KW, Qiang B, Sparkes JD, et al. Effects of
distal embolization on the timing of platelet and inflammatory cell
activation in interventional coronary no-reflow. Thromb Res. 2010;126:50–5.
29. Vilahur G, Juan-Babot O, Pena E, Onate B, Casani L, Badimon L. Molecular
and cellular mechanisms involved in cardiac remodeling after acute
myocardial infarction. J Mol Cell Cardiol. 2011;50:522–33.
30. Hayashidani S, Tsutsui H, Ikeuchi M, Shiomi T, Matsusaka H, Kubota T, et al.
Targeted deletion of MMP-2 attenuates early LV rupture and late
remodeling after experimental myocardial infarction. Am J Physiol Heart
Circ Physiol. 2003;285:H1229–35.
31. Matsunaga T, Abe N, Kameda K, Hagii J, Fujita N, Onodera H, et al.
Circulating level of gelatinase activity predicts ventricular
remodeling in patients with acute myocardial infarction. Intl J Cardiol.
2005;105:203–8.
32. Sussman MA, Volkers M, Fischer K, Bailey B, Cottage CT, Din S, et al.
Myocardial AKT: the omnipresent nexus. Physiol Rev. 2011;91:1023–70.
33. Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K. Akt promotes survival of
cardiomyocytes in vitro and protects against ischemia-reperfusion injury in
mouse heart. Circulation. 2000;101:660–7.
34. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, et al.
GLP-1R agonist liraglutide activates cytoprotective pathways and improves
outcomes after experimental myocardial infarction in mice. Diabetes.
2009;58:975–83.
35. Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM. Postconditioning: a form
of “modified reperfusion” protects the myocardium by activating the
phosphatidylinositol 3-kinase-Akt pathway. Circ Res. 2004;95:230–2.
36. Dorge H, Schulz R, Belosjorow S, Post H, van de Sand A, Konietzka I, et al.
Coronary microembolization: the role of TNF-alpha in contractile
dysfunction. J Mol Cell Cardiol. 2002;34:51–62.
37. Breuckmann F, Nassenstein K, Bucher C, Konietzka I, Kaiser G, Konorza T,
et al. Systematic analysis of functional and structural changes after coronary
microembolization: a cardiac magnetic resonance imaging study. JACC
Cardiovasc Img. 2009;2:121–30. doi:10.1016/j.jcmg.2008.10.011.
38. Heusch G, Kleinbongard P, Bose D, Levkau B, Haude M, Schulz R, et al.
Coronary microembolization: from bedside to bench and back to bedside.
Circulation. 2009;120:1822–36.
39. Li S, Zhong S, Zeng K, Luo Y, Zhang F, Sun X, et al. Blockade of NF-kappaB
by pyrrolidine dithiocarbamate attenuates myocardial inflammatory
response and ventricular dysfunction following coronary microembolization
induced by homologous microthrombi in rats. Bas Res Cardiol.
2010;105:139–50.
40. Svilaas T, Vlaar PJ, van der Horst IC, Diercks GF, de Smet BJ, van den Heuvel
AF, et al. Thrombus aspiration during primary percutaneous coronary
intervention. N Engl J Med. 2008;358:557–67.
41. Lagerqvist B, Frobert O, Olivecrona GK, Gudnason T, Maeng M, Alstrom P,
et al. Outcomes 1 year after thrombus aspiration for myocardial infarction.
N Engl J Med. 2014;371:1111–20.
42. Jolly SS, Cairns JA, Yusuf S, Meeks B, Pogue J, Rokoss MJ, et al. Randomized
trial of primary PCI with or without routine manual thrombectomy.
N Engl J Med. 2015;372:1389–98.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Thomas et al. Journal of Cardiovascular Magnetic Resonance  (2015) 17:106 Page 13 of 13
